| UPDATED: 17:03, Mon, Dec 14, 2020
Link copied Sign up for FREE health tips to live a long and happy life
SUBSCRIBE Invalid email
When you subscribe we will use the information you provide to send you these newsletters. Sometimes they ll include recommendations for other related newsletters or services we offer. Our Privacy Notice explains more about how we use your data, and your rights. You can unsubscribe at any time.
Pharmaceutical services company Open Orphan announced it had received approval from the MHRA on Monday and that it was ready to conduct a phase one study of Covi-Vac, the COVID-19 nasal vaccine, in collaboration with US biotech Codgenix. Open Orphan’s subsidiary, hVIVO, will evaluate safety and immunogenicity of single-dose nasal vaccine candidate in 48 healthy young adult volunteers in its facility in Whitechapel, London.
New-york
United-states
United-kingdom
London
City-of
Whitechapel
Tower-hamlets
Britain
Cathal-friel
Pfzier-biontech
Pfizer
Co-united-kingdom